VCYT
Veracyte, Inc.
NASDAQ · USHealthcareBiotechnology
$57.26-3.16%
Price as of Jul 20, 2026
VCYT profitability
Veracyte, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 71.3%
- EBITDA margin
- 20.7%
- EBIT margin
- 12.5%
- Net margin
- 16.2%
- Free cash flow margin
- 28.6%
Returns
- Return on equity
- 6.5%
- Return on assets
- 6.1%
- Return on invested capital
- 4.9%
- Asset turnover
- 0.38x
Cash efficiency
- Cash from operations
- $166.2M
- Cash per share
- $5.50
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.